CCL5 and hepatocellular carcinoma: Circular RNA studies revealed that circETFA in HCC can prolong the half‐life of CCL5 mRNA by recruiting eukaryotic translation initiation factor (EIF) 4A3 and acting as a sponge for hsa‐miR‐612 to inhibit the silencing effect of hsa‐miR‐612 on CCL5, thereby promoting HCC progression by increasing CCL5 expression [26].